🔴 SeaStar Medical is trading 6.4% down in pre-market with no clear catalyst reported

SeaStar Medical is trading at $1.91, down 6.37%, with no clear company-specific catalyst reported for its November 5 pre-market decline.

• Latest company news was its November 4 announcement that it will report third-quarter results on November 11; this is a scheduled event, not an earnings release.
• The FDA confirmed November 3 that QUELIMMUNE’s post-approval study requirements were fulfilled. This positive access-related news is not an evident explanation for the decline.
• Healthcare-sector strength is contrary to the stock’s move, while the supplied broad-market indicators are mixed.